Loading clinical trials...
Loading clinical trials...
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: An Open-label Multicenter Extension Study
Conditions
Interventions
treprostinil diethanolamine
Locations
26
United States
University of Alabama - Birmingham - Arthritis Clinical Intervention Program
Birmingham, Alabama, United States
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
UCLA
Los Angeles, California, United States
Barbara Davis Centre
Aurora, Colorado, United States
University of Connecticut Health Center
Farmington, Connecticut, United States
Georgetown University - Dept. of Medicine/Rheumatology
Washington D.C., District of Columbia, United States
Start Date
September 1, 2009
Primary Completion Date
September 1, 2011
Completion Date
September 1, 2011
Last Updated
June 18, 2024
NCT06947460
NCT07413341
NCT04402086
NCT07295847
NCT07361094
NCT07339540
Lead Sponsor
United Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions